Skip to main content
OpenTrials
Completed

NCT Number: NCT00549939

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of neuropathic etiology and detrusor LPP ≥ 40 cm H2O.

Secondary objectives were:

* To investigate the safety and tolerability of two doses of Alfuzosin in comparison to Placebo in children and adolescents, * To evaluate the effects of the two doses of Alfuzosin in comparison to Placebo on:

* Detrusor compliance, * Urinary tract infection, * To investigate the pharmacokinetics of Alfuzosin (population kinetics), * To evaluate the 12-month long-term safety of Alfuzosin 0.1 mg/kg/day and 0.2 mg/kg/day.

The study consisted of 2 periods:

* a 12-week double blind treatment period where patients were to receive either Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day or placebo then, * a 40-week open label extension treatment period where patients were to receive either Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neurogenic Urinary Bladder Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Urinary Bladder Diseases Urinary Bladder, Neurogenic Urogenital Diseases Urologic Diseases

Age range

2 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sanofi-Aventis Administrative Office, Sofia, Bulgaria

Loading trial locations.

About this study

Patients who met the study entry criteria were randomized (2:1:2:1) to one of the 4 dosage groups (Alfuzosin 0.1 mg/kg/day, matching placebo 0.1 mg/kg/day, Alfuzosin 0.2 mg/mg/kg, matching placebo 0.2 mg/kg/day).

Patients received their treatment using either solution or tablet formulation depending on age as follows:

  • Solution to children 2-7 years of age or, children and adolescents 8-16 years of age if they were unable to swallow tablets or they preferred to take the solution or if they had a body weight < 30kg. The daily dose was devided in 3 doses given at at breakfast, lunch and dinner.
  • Tablet to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30kg. The daily dose was devided in 2 doses given at at breakfast and dinner.

Patients who have completed the 12-week double-blind phase were offered to continue in the 40-week open-label extension study.

  • Patients receiving Alfuzosin continued with their dosing regimen.
  • Patients receiving Placebo were switched to Alfuzosin with a dose corresponding to their randomization dose group.

All patients had a one-week follow-up period after last dose intake.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with elevated detrusor Leak Point Pressure (LPP) of neuropathic etiology and Detrusor LPP ≥ 40 cm H2O and < 100 cm H2O.

Exclusion criteria

  • Urological surgery in the last 4 months prior to the study,
  • Patients who have urethral dilatation in the last 3 months prior to the baseline urodynamic assessment,
  • α-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment,
  • Detrusor injections of botulinum toxin in the last 6 months,
  • Urological diseases/conditions other than functional bladder obstruction of neuropathic etiology that can lead to upper urinary tract dilatation (e.g., bladder anomalies, ureterocele),
  • History of intolerance to α-blocker therapy,
  • Orthostatic hypotension,
  • History of risk factors for Torsade de pointes (e.g., family history of Long QT Syndrome).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Alfuzosin

Drug

Form: solution or tablet according to age

Route: oral

Dose: daily dose adjusted to body weight

Other names: SL770499

Placebo

Drug

Form: matching solution or matching tablet according to age

Route: oral

Dose: daily dose adjusted to body weight

Primary outcomes

  1. Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O

    Time frame: 12 weeks (double blind treatment period)

    Detrusor Leak Point Pressure (LPP) was measured by cystometry.

    For each measure, 2 or 3 cystometries were carried out depending on the difference between the 2 first LPP values (if the difference ≥ 20 cm H2O, a 3rd cystometry was done). The lowest value was retained.

    Investigators reading was then consolidated by the review of all cystometry data by 2 external "Expert Reviewers", who were blinded for the study treatment.

    The analysis was performed on consolidated investigators data (i.e. endorsed by the Investigator taking into account reviewers opinion).

Secondary outcomes

  1. Detrusor Leak Point Pressure (LPP)

    Time frame: baseline and 12 weeks (double blind treatment period)

    Detrusor Leak Point Pressure (LPP) was assessed at baseline and 12 weeks as described for the primary outcome measure.

  2. Absolute Change in Detrusor LPP

    Time frame: 12 weeks ((double blind treatment period)

    Absolute change = Detrusor LPP at 12 weeks - Detrusor LPP at baseline

  3. Relative Change in Detrusor LPP

    Time frame: 12 weeks (double blind treatment period)

    Relative change = 100 * (Detrusor LPP at 12 weeks - Detrusor LPP at baseline) / Detrusor LPP at baseline

  4. Detrusor Compliance

    Time frame: baseline and 12 weeks (double blind treatment period)

    Detrusor compliance is defined as the relationship between change in detrusor volume and change in detrusor pressure.

    It was calculated by dividing the volume change (ΔV) by the change in detrusor pressure (Δpdet) during that change in detrusor volume at leak point (C= ΔV/Δpdet).

  5. Relative Change in Detrusor Compliance

    Time frame: 12 weeks (double blind treatment period)

    Relative change = 100 * (Detrusor compliance at 12 weeks - Detrusor compliance at baseline) / Detrusor compliance at baseline

  6. Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes

    Time frame: 12 weeks (double blind treatment period)

    When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture.

    A symptomatic UTI was defined as the presence of symptoms and a positive culture with > 100 000 Colony Forming Units (CFUs) with a single organism.

  7. Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes

    Time frame: 52 weeks (double blind treatment period + open label extension treatment period)

    Symptomatic UTI episodes were assessed similar to the previous outcome measure but for a longer follow-up period.

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension

Acronym: ALFACHIN

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Oct 26, 2007
Registry last updated
Oct 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.